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Abstract
Background: The aim of this study is to provide data on long term results of gastric cancer
surgery and in particular the D1 gastric resection.
Methods: In the period 1992-2004, 235 male and female patients with a median age of 69 and 70
years respectively, were included with a stage I through IV gastric carcinoma, of which 37% was
stage IV disease. Whenever possible a gastric resection was performed. In case of obstructive
tumour growth palliation was provided by means of a gastro-enterostomy.
Results:  Gastrectomy with curative intent was achieved in 50%, palliative resection in 22%,
palliative surgery (gastro-enterostomy) in 10% and in 18% irresectability led to surgical exploration
only. Patients in the curative intent group demonstrated a 47% survival after 5 years and up to 34%
after 10 years. However metastases where seen in 32% of the patients after gastrectomy with
curative intent. After palliative resection one year survival was 57%, whereas 19% survived more
than 3 years. Overall postoperative morbidity and mortality rates were 40% and 13% respectively.
Conclusion: Long term survival after surgery for gastric cancer is poor and is improved by early
detection and radical resection. However, palliative resection showed improved survival compared
to gastro-enterostomy alone or no resection at all which may be an effect of adjuvant therapy.
Background
Gastric carcinoma remains one of the leading causes of
cancer related deaths, although the worldwide incidence
is declining [1]. Prognosis has improved only moderately
with low overall survival rates. Surgical excision offers the
only possibility for cure or long term survival [2]. Japanese
surgeons were the first to implicate extended lym-
phadenectomy in an effort to reduce local recurrence and
improve survival [3]. This included removal of 12 differ-
ent lymph node stations grouped around the stomach and
the arteries originating from the celiac trunk as well as
resection of the spleen and pancreas tail, although
splenectomy and pancreas tail resection is no longer man-
datory when lymph nodes from these stations can be oth-
erwise removed. This D2 resection has been compared
with the D1 resection which entails only removal of the
stomach and its directly surrounding lymph nodes.
Although Japanese studies demonstrated increased sur-
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vival with low morbidity and postoperative mortality, two
large multi centre randomised controlled studies were
unable to reproduce these results and demonstrated
higher morbidity and mortality rates, this same conclu-
sion was drawn by an extensive literature review [2,4,5].
The D1 resection is therefore still considered the standard
treatment for gastric cancer surgery in most western coun-
tries.
In recent years the relationship between hospital volume
and outcome has been studied for several types of surgical
therapies including gastric surgery [6,7]. Although most
papers report on short term outcomes, long term survival
rates are at least as relevant but these types of data are
scarce. When studying recent literature it seems mostly
data from patients undergoing a gastric resection proce-
dure are presented, although a substantial part of the
patients with gastric cancer present at a stage when resec-
tion is not possible anymore. In order to provide better
insight in the short and long term outcomes of the surgi-
cal treatment of gastric cancer we evaluated the results
from patients treated during the last 12 years. Further-
more, we compared these results with those obtained
from the literature.
Methods
A total of 235 patients treated in our department for his-
tologically proven gastric carcinoma between 1992 and
2004, were identified from a surgical database. This data-
base was specifically designed for our surgical department
to enable us to collect data prospectively on surgical inter-
ventions and register complications as well as others
details in the postoperative period. This database includes
demographic parameters, as well as data concerning ther-
apeutic interventions and complications. Additional
information such as tumour stage and pathology reports
was gathered retrospectively from the individual patient
files, most of which are already part of our electronic
patient file registry that was started in the year 1999.
When necessary the general practitioner was contacted for
additional information.
Preoperative work-up consisted standard of gastroscopy,
upper gastro-intestinal series and blood count. Computed
tomography (CT) scan was only performed in 50 patients
in cases where metastasis where suspected. However, the
most recent national oncology guidelines, do not advise
CT scan as standard preoperative diagnostic work-up.
Patients were referred by the gastroenterologists.
Gastrectomy was performed using a standard D1 dissec-
tion [8]. Tumour type and location within the stomach
were registered as well as histological grade. Pathologic
staging was reported according to the TNM grading system
[9]. Life table analysis was performed to evaluate survival
in all patient groups.
Subgroup analysis was performed for tumour stage, type
and location, different surgical interventions, age and co-
morbidity. Statistical analysis was performed for survival
data of the different surgical intervention groups using
SPSS statistical software version 12.0.01 (Chicago, Illi-
nois, USA).
Results
Patients
A total of 235 patients were included, 141 male and 94
female with a median age of 69 years (range 37–88) and
70 years (range 34–91) respectively, with a median fol-
low-up of 11.9 months. Over 99% of the patients had
symptoms related to gastric carcinoma, most often con-
sisting of weight loss, pain and anorexia. Only 2 gastric
cancers were detected in symptom free patients, both of
which were operated upon. Co-morbidity was present in
138 patients (59%), various patients having more than
form of co-morbidity. This consisted primarily of cardio-
vascular and pulmonary diseases, specifications of which
are found in table 1.
Tumour
Most tumours were located in the antrum and corpus.
Twelve percent was located in the cardia, and in 9% linitis
plastica (whole stomach) was found (table 2). All
tumours consisted of adenocarcinoma, the majority of
which were high graded. More than a third of the entire
population presented with stage IV disease.
In the subgroup of patients undergoing resection with cur-
ative intent disease stages were as follows: 10.7% stage Ia,
25.6% stage Ib, 24% stage II, 26% stage IIIa, 1.7% stage
IIIb, 6.6% stage IV and in 5% stage could not be deter-
mined.
Table 1: Comorbidity in gastric cancer patients
Comorbidity No. of Patients %
Cardiovascular 87 37
Pulmonary 24 10
Diabetes 19 8
Other carcinoma 20 9
Previous gastrointestinal surgery 18 8
Body Mass Index ≥ 30 12 5
Clotting disorder 2 1
Other 11 5World Journal of Surgical Oncology 2007, 5:81 http://www.wjso.com/content/5/1/81
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Surgical procedure
If possible, patients in our population underwent a D1
resection (table 3). When radical resection was impossi-
ble, the other options were palliative resection (51
patients), gastrointestinal bypass (23 patients) or surgical
exploration (43 patients). Postoperative morbidity
occurred in 40% of all patients. We discriminated
between direct surgical complications and secondary mor-
bidity (table 4). Patients with preoperative co-morbidity
were slightly more at risk for developing postoperative
morbidity (42% versus 37%) compared to the other
patients. When only surgical exploration was performed
postoperative morbidity decreased to 21%.
Length of stay for surgical patients varied between 0 and
126 days with a mean of 13.7 days. Patients with co-mor-
bidity were, on mean, hospitalised 3 days longer. Only
patients in the explorative surgery group had a signifi-
cantly shorter duration of admission (7 days).
Surgeons
The majority of surgical procedures (200) were performed
by a total of 6 gastrointestinal surgeons. One general sur-
geon performed 23 operations and the remaining 13
operations were performed by three different general sur-
geons during night time emergency procedures.
The mean of surgical procedures per (gastrointestinal)
surgeon per year varied from 3 to 13. The most experi-
enced surgeon performed a total of 87 procedures. Com-
plication rate varying from minor to major was on average
40%. Only the most experienced surgeon had a percent-
age of 32. The general surgeon had a complication rate of
43%.
Mortality
Perioperative mortality was defined as mortality within 30
days or, when still admitted beyond 30 days, in-hospital
mortality. Perioperative mortality was 14% for the entire
population. In the subgroup of patients undergoing sur-
gery with curative intent, regardless of age, postoperative
mortality was 13%. However, age was an independent
risk-factor. Mortality rates for patients up to 75 years and
patients over 75 years of age were 10% and 17% respec-
tively. For resection with curative intent mortality rates for
these age groups were 8% vs. 17% respectively, the former
percentage approximating the Dutch gastric cancer trial
data.
Table 3: Surgical interventions in study population
Resection type No. of patients %
Curative resection 118 50
Total gastrectomy 34 14
Partial gastrectomy 80 34
Gastrectomy after 
former B1 resection
21
Oesophagus-stomach 2 1
Palliative resection 51 22
Total gastrectomy 16 7
Partial gastrectomy 34 14
Oesophagus-stomach 1 0
Palliative surgery 23 10
Gastro-enterostomy 23 10
Explorative 43 18
Table 2: Patient, surgery and morbidity data
No. of patients %
Tumour location
Antrum 109 46
Corpus 44 19
Fundus 2 1
Overlap 13 6
Cardia 28 12
Whole stomach 22 9
Residual stomach 11 5
Unknown 6 3
Tumour type
Adenocarcinoma 235 100
Stage
Ia 12 5
Ib 30 13
II 33 14
IIIa 55 23
IIIb 9 4
IV 88 37
Unknown 8 3
Surgery
Curative resection 118 50
Palliative resection 51 22
Palliative surgery 23 10
Explorative surgery 43 18
Postoperative morbidity
93 40
Adjuvant therapy
37 16World Journal of Surgical Oncology 2007, 5:81 http://www.wjso.com/content/5/1/81
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Survival
Overall survival ranged from 1 month to 142.5 months.
When divided for different disease stages an obvious
inverse relation between stage group and survival was
detected (Figure 1; additional file 1) The 5 year survival
for the different stages 1a, 1b, 2, 3a, 3b and 4 was: 79%,
57%, 41%, 26%, 0% and 13% respectively. However, dis-
ease free survival rates were substantially lower, also after
prolonged follow-up periods (Figure 2 and additional file
1). The mean disease free survival for the different stages
1a, 1b, 2, 3a, 3b and 4 was: 60%, 40%, 15%, 9%, 0% and
1% respectively. In the Netherlands registration of sur-
vival of gastric carcinoma was so far only performed in
two regions, the survival data from the neighbouring
region are shown for comparison (Figure 3).
When focusing on surgical intervention, survival was
highest in the curative resection group (N = 118) with a 10
year survival of 34% vs. 9% for palliative resection (N =
51). Palliative surgery (gastro-enterostomy, N = 23)
showed a 12% survival over 10 years, whereas no patients
survived surgical exploration (N = 43) over 2 years (Figure
4). Mean survival (±standard error) in the different surgi-
cal groups: curative resection, palliative resection, pallia-
tive surgery and explorative surgery was: 68%(±6),
25%(±6), 4%(±0.7) and 7%(±1) respectively.
Curative resection resulted in a significantly higher sur-
vival than palliative resection (p = 0.0007) and palliative
resection in itself was better than gastro-enterostomy and
explorative surgery (p = 0.0017) using the Wilcoxon
(Gehan) test. During follow-up in 32% of the patients in
the curative resection group metastases where detected.
Palliative resection resulted in a 57% 1-year survival, but
decreased to 9% at 5 years (Additional File 2). No differ-
ence in survival was noted when determined for the vari-
ous tumour locations, except for the whole stomach
(linitis plastica) group, which carried the worst prognosis.
Adjuvant therapy
Of all surgical patients included in this study, 37 patients
(15%) received adjuvant therapy. This consisted of radio-
therapy (11%), chemotherapy (76%), or a combination
of both (13%). Of these patients 22 (59%) had a stage 4
tumour. Median survival after adjuvant therapy was 20
months.
Discussion
The only possibility for curative treatment of gastric can-
cer remains surgical resection. However, patients typically
present with an advanced stage as illustrated by our data
where 37% of the population presented with stage 4 dis-
ease, resulting in only 50% of the patients to be eligible
for surgery with curative intent. Furthermore, gastric can-
cer is more frequent in the older population (31% of the
patients 75 years and older in our cohort) who have more
co-morbidity and higher postoperative mortality rates
[10] as confirmed by our data.
Survival after a D1 gastric resection with curative intent
amounted to a 47% survival rate after 5 years and even a
34% survival after 10 years which demonstrates the
importance of radical surgery. However, more extensive
(D2) resection has not resulted in improved outcome in
Western centres despite promising results from Japanese
groups [3]. On the other hand, even in the curative surgery
group, during longer follow-up 30% of the patients
develop metastases. Apparently, (micro) metastases are
often not recognized initially, ultimately leading to pro-
gressive disease. Although chemotherapy is not routinely
Survival in months of all gastric cancer patients divided per  stage Figure 1
Survival in months of all gastric cancer patients divided per 
stage.
Table 4: Surgical complications and morbidity in study population
Surgical complications % No. of patients Secondary morbidity % No. of patients
Anastomotic leak 6.0 14 Cardiovascular 8.5 20
Wound infection 2.1 5 Pulmonary 9.8 23
Motility disturbance 3.4 8 Urinary tract infection 3.0 7
Gastrointestinal 
damage *
4.3 10 Other 9.8 23
* splenic puncture, gastric perforation, hemorrhageWorld Journal of Surgical Oncology 2007, 5:81 http://www.wjso.com/content/5/1/81
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applied in gastric cancer surgery, more studies are under-
taken to explore it's possibilities and this may well
improve disease free survival [11,12]. In our series for
example, patients that lived longest (up to 50 months)
belonged to the curative surgery group except for one
patient that underwent palliative resection of a stage 3a
tumour, combined with adjuvant chemotherapy, who
survived up to 11 years without signs of metastases or
recurrent disease.
Whereas data on the results of surgery for gastric cancer
are available from several large multi centre studies, our
results represent the outcome of the entire population
treated surgically for stomach cancer. The selection bias in
these larger studies probably explains for a large part the
(relatively small) differences with the outcomes reported
in this study. On the other hand, our data compare well
with the long term results and stage dependent survival
after gastric cancer surgery reported by the United States
National Cancer Database [13] (table 6).
When curative resection was not possible, palliative resec-
tion was performed in a limited number of cases. Interest-
ingly palliative resection seemed to improve survival
compared to other palliative procedures, especially in the
first postoperative year (Figure 4; additional file 2). How-
ever, these 2 palliatively treated groups (resection versus
exploration or gastroenterostomy) differed with regard to
tumour stage (less patients with stage 4 disease in the
resection group) and appliance of adjuvant therapy (more
frequent use of adjuvant chemotherapy in the resection
group) (table 5). Which factor contributes most to this
difference cannot be deduced from our data. The combi-
nation of cytoreduction and chemotherapy has been
reported to result in a modest survival advantage [14].
Developments using hyperthermic intraperitoneal chem-
otherapy after cytoreduction show promising results,
although residual tumour status remained the most
important predictor of survival [15].
The other strategy to improve outcome of treatment for
gastric cancer is to aim for early detection of gastric carci-
noma. Unfortunately symptoms often present late in the
course of the disease and usually are non-specific. Popula-
tion based screening programs by means of gastroscopy
has not been feasible in the western world due to low pre-
test probability and relative high cost.
Table 5: Palliative resection vs no resection; patient 
characteristics
Palliative 
resection (R1/R2)
No resection 
(GE/exploration)
no. of patients 51 66
median age (yr) 70 68
comorbidity (%) 63 47
complications (%) 39 21
adjuvant therapy (%) 31 18
no. of patients: male 34 43
no. of patients: female 17 23
admission days
median (range) 12 (1–66) 8 (0–45)
30 day mortality (%) 16 20
6 months survival % 67 27
1 yr survival % 43 3
2 yr survival % 18 1
stage 1a (No. Of patients) 0 0
stage 1b (No. Of patients) 0 0
stage 2 (No. Of patients) 3 1
stage 3a (No. Of patients) 17 6
stage 3b (No. Of patients) 4 3
stage 4 (No. Of patients) 27 53
unknown stage 0 3
Disease free survival in months of all gastric cancer patients  divided per stage Figure 2
Disease free survival in months of all gastric cancer patients 
divided per stage.
Survival in years of gastric cancer patients divided per stage  in a neighbouring region in the Netherlands Figure 3
Survival in years of gastric cancer patients divided per stage 
in a neighbouring region in the Netherlands.World Journal of Surgical Oncology 2007, 5:81 http://www.wjso.com/content/5/1/81
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Zappa et al., combined a positive faecal occult blood test
(FOBT) and a negative colonoscopy to select patients for
gastroscopy in a large screening project. Still the number
needed to screen was 254 without proven benefit on sur-
vival of the identified gastric cancer [16]. In a recent pub-
lication serum pepsinogen testing was reviewed to
identify high risk patients, possibly combined with a heli-
cobacter pylori test to reduce the amount of individuals
that need gastroscopic screening [17].
Postoperative morbidity was high (40%) as this reflects all
in hospital morbidity, both directly related to surgery,
such as wound infections and anastomotic leakage, as
well as postoperative morbidity in general, such as pul-
monary or urinary tract infections. This figure is in line
with results from other centres [18]. The underlying rea-
sons are related to the fact that the population is relatively
old with significant co-morbidities but nutritional deple-
tion may also play a role. Therefore, careful attention
should be paid to the perioperative care in this fragile
patient group in order to improve outcomes.
Conclusion
In conclusion, gastric cancer treatment is first and fore-
most favoured with early detection, as many studies have
demonstrated stage dependent survival ratios. In general
practice however, most patients are detected late in the
course of disease as illustrated by the fact that only 50% of
the patient in our series were operated with curative
intent. However, the efficacy of screening programs needs
to be improved prior to widespread implementation in
western societies. Palliative resection, if possible, in com-
bination with adjuvant chemotherapy may add to postop-
erative survival at least during the first year after surgery
when compared with palliative surgery such as a gastro-
enterostomy although this remains to be confirmed. Post-
operative mortality and morbidity are relatively high and
dictate optimal perioperative care.
Because the prognosis after surgery is determined prima-
rily by the radicality of the resection, we believe that this
type of surgery should be performed by dedicated sur-
geons. Further improvements in outcome probably can be
expected by application of perioperative (neo) adjuvant
therapies.
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Table 6: Survival after gastric cancer surgery in our study 
compared to the US cancer database
Tumorstage Survival at 5 
years US 
(gastrectomy)
survival at 5 
years in Sittard
number of 
patients per stage
Ia 78% 79% 12
Ib 58% 57% 30
II 34% 41% 33
IIIa 20% 26% 55
IIIb 8% 0% 9
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